These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36127726)

  • 21. A Comparison of the Efficacy of Once-Daily Fluticasone Furoate/Vilanterole with Twice-Daily Fluticasone Propionate/Salmeterol in Elderly Asthmatics.
    Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Abo M; Kasahara K
    Drug Res (Stuttg); 2018 Jan; 68(1):38-44. PubMed ID: 28926855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom control in patients with asthma using inhaled corticosteroids/long-acting β
    Averell CM; Laliberté F; Germain G; Duh MS; Lima R; Mahendran M; Slade DJ
    J Asthma; 2022 Sep; 59(9):1805-1818. PubMed ID: 34375568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
    Oliver AJ; Covar RA; Goldfrad CH; Klein RM; Pedersen SE; Sorkness CA; Tomkins SA; Villarán C; Grigg J
    Respir Res; 2016 Apr; 17():37. PubMed ID: 27044326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
    Bateman ED; O'Byrne PM; Busse WW; Lötvall J; Bleecker ER; Andersen L; Jacques L; Frith L; Lim J; Woodcock A
    Thorax; 2014 Apr; 69(4):312-9. PubMed ID: 24253831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials.
    Gross AS; Goldfrad C; Hozawa S; James MH; Clifton CS; Sugiyama Y; Jacques L
    BMC Pulm Med; 2015 Dec; 15():165. PubMed ID: 26704701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I; Williams M; Power S; Pilcher J; Weatherall M; Baines A; Moynihan J; Kempsford R; Beasley R;
    Respir Med; 2016 Oct; 119():115-121. PubMed ID: 27692131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction.
    Martin N; Weiler JM; Pearlman D; Jacques L; Nunn C; Forth R; West S; Dunn K; O'Byrne PM
    J Asthma; 2020 Apr; 57(4):431-440. PubMed ID: 30795705
    [No Abstract]   [Full Text] [Related]  

  • 29. Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
    Rodrigo GJ; Plaza V
    Ann Allergy Asthma Immunol; 2016 Jun; 116(6):565-70. PubMed ID: 27117053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study.
    Svedsater H; Jones R; Bosanquet N; Jacques L; Lay-Flurrie J; Leather DA; Vestbo J; Collier S; Woodcock A
    Respir Med; 2018 Aug; 141():198-206. PubMed ID: 30053967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
    Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences.
    Svedsater H; Doll HA; Macey J; Miles G; Bradshaw L; Vanya M
    Adv Ther; 2018 Sep; 35(9):1378-1399. PubMed ID: 30105658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
    Woodcock A; Vestbo J; Bakerly ND; New J; Gibson JM; McCorkindale S; Jones R; Collier S; Lay-Flurrie J; Frith L; Jacques L; Fletcher JL; Harvey C; Svedsater H; Leather D;
    Lancet; 2017 Nov; 390(10109):2247-2255. PubMed ID: 28903864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma.
    Chang V; Gray EL; Thomas PS
    Expert Rev Respir Med; 2016 Oct; 10(10):1069-78. PubMed ID: 27599692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG; Prosser TR
    Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.
    Kempsford R; Allen A; Bal J; Rubin D; Tombs L
    Br J Clin Pharmacol; 2013 Jun; 75(6):1478-87. PubMed ID: 23116485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms: Post hoc analyses of three randomized controlled trials.
    Kerwin E; Barnes N; Gibbs M; Leather D; Forth R; Jacques L; Yates LJ
    J Asthma; 2018 Aug; 55(8):890-897. PubMed ID: 28783413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma.
    Vallejo-Aparicio LA; Molina J; Ojanguren I; Viejo Casas A; Huerta A; Svedsater H
    Eur J Health Econ; 2020 Feb; 21(1):7-17. PubMed ID: 31549255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.